Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Surufatinib |
| Trade Name | |
| Synonyms | Sulfatinib|HMPL-012 |
| Drug Descriptions |
Surufatinib (HMPL-012) is a dual VEGFR/FGFR1 inhibitor, which potentially results in reduced cell proliferation and migration, alteration of the tumor microenvironment, and inhibition of tumor angiogenesis and growth (PMID: 37361567). |
| DrugClasses | FGFR1 Inhibitor 28 VEGFR Inhibitor (Pan) 36 |
| CAS Registry Number | 1308672-74-3 |
| NCIT ID | C116066 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Doxorubicin + Surufatinib | Doxorubicin Surufatinib | 0 | 0 |
| Gemcitabine + Surufatinib | Gemcitabine Surufatinib | 0 | 1 |
| Surufatinib | Surufatinib | 0 | 3 |
| Surufatinib + Tislelizumab | Surufatinib Tislelizumab | 0 | 1 |
| Surufatinib + Toripalimab-tpzi | Surufatinib Toripalimab-tpzi | 0 | 0 |